Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo
- Biggest single investment in Grünenthal’s history that will significantly strengthen the company’s leading position in pain management; - Gastroprotective therapies to address a high unmet medical need[1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs).
- 30.10.2018, 10:24
- Kategoria: Biznes i finanse
- Źródło: APA-OTS